Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses

A technology for hypokalemia and hypomagnesemia is applied in the field of medicines for the treatment of hypokalemia and hypomagnesemia, which can solve the problems of poor absorption and availability, large molecular weight, large molecular structure, etc. The effect of avoiding alkalosis and improving absorption and utilization

Active Publication Date: 2006-09-27
LIAONING YAOLIAN PHARMA
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the clinical application of magnesium aspartate, it is also found that due to its large molecular structure, complex spatial structure, and large molecular weight, it leads to poor absorption and utilization.
At the same time, due to the structural composition of magnesium aspartate alkaline earth metal, it is easy to destroy the acid-base balance in the body and cause alkalosis when used for a long time or in large quantities.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses
  • Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses
  • Electrolyte replenisher for treating hypopotassaemia hypomagnesemia and its uses

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] 1. Tablet prescription: magnesium aspartate hydrochloride 100g

[0027] Potassium Aspartate 10g

[0028] Starch 380g

[0029] Makes 1000 pieces

[0030] 2. Preparation process: Take 100g of magnesium aspartate hydrochloride, 10g of potassium aspartate and 380g of starch for mixing and crushing, add 10g of starch slurry and mix to make soft material, granulate with 14 or 16 mesh sieve, dry, Granules, compressed tablets, coated, subpackaged. Usage: Take orally, 1 tablet at a time, 2 times a day. One month is a course of treatment.

Embodiment 2

[0032] 1. Tablet prescription: magnesium aspartate hydrochloride 42.5g

[0033] Potassium Aspartate 425g

[0034] Starch 120g

[0035] Made into 2000 pieces

[0036] 2. Preparation process: take 42.5g of magnesium aspartate hydrochloride, 425g of potassium aspartate and 120g of starch, mix and pulverize, add 10g of starch slurry and mix to make soft material, granulate with 14 or 16 mesh sieve, dry, Whole grains, compressed into tablets, coated and subpackaged. Usage: Take orally, 1 tablet at a time, 2 times a day. One month is a course of treatment.

Embodiment 3

[0038] 1. Tablet prescription: magnesium aspartate hydrochloride 40g

[0039] Potassium Aspartate 20g

[0040] Starch 30g

[0041] Makes 1000 pieces

[0042] 2. Preparation process: Take 40g of magnesium aspartate hydrochloride, 20g of potassium aspartate and 30g of starch, mix and pulverize, add 10g of starch slurry and mix to make soft material, granulate with 14 or 16 mesh sieve, dry, Granules, compressed tablets, coated, subpackaged. Usage: Take orally, 1 tablet at a time, 2 times a day. One month is a course of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The electrolyte replenishing agent for treating hypokalemia and hypomagnesemia includes the medicine with magnesium aspartate hydrochloride and potassium aspartate in the weight ratio of 1 to 0.1-10 as active components. The electrolyte replenishing agent can replenish body with potassium and magnesium ions, maintain the intracellular non-dissociation acid-base metabolism balance and raise the bioavailability of potassium and magnesium ions in body.

Description

technical field [0001] The invention relates to a medicine for treating hypokalemia and hypomagnesemia, in particular to an electrolyte supplement for treating hypokalemia and hypomagnesemia, which can be used for treating cardiovascular diseases and acute and chronic liver dysfunction. Background technique [0002] Cardiovascular disease has become the number one enemy of human health. According to the statistics of the World Health Organization, cardiovascular disease kills 12 million people every year, which is close to a quarter of the total death toll of the world's population. In the past ten years, with the development of medical technology, cardiovascular mortality has declined, but it still ranks first in the cause of death, seriously threatening the quality of life of human beings. With the development of society, more and more people suffer from liver disease due to environmental pollution, excessive mental stress and other unhealthy lifestyles such as smoking an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/198A61P3/12A61P9/00A61P1/16
Inventor 于航丁红梅
Owner LIAONING YAOLIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap